Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 30;8(2):00129-2022.
doi: 10.1183/23120541.00129-2022. eCollection 2022 Apr.

A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study

Janwillem Kocks  1   2   3 , Marjan Kerkhof  1 , Jan Scherpenisse  4 , Aimée van de Maat  1 , Iris van Geer-Postmus  1 , Thomas le Rütte  1 , Jan Schaart  5 , Reinold O B Gans  6 , Huib A M Kerstjens  2   7
Affiliations

A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study

Janwillem Kocks et al. ERJ Open Res. .

Abstract

This study suggests caution when prescribing systemic corticosteroids to patients with #COVID19 who show mild-to-moderate pulmonary symptoms because a harmful effect cannot be excluded https://bit.ly/3P4nOjQ.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J. Kocks, M. Kerkhof, A. van de Maat, I. van Geer-Postmus and T. le Rütte were employed by the General Practitioners Research Institute (GPRI) at the time of the study. In the past 3 years (2019–2022), the GPRI conducted investigator- and sponsor-initiated research funded by noncommercial organisations, academic institutes and pharmaceutical companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis and Teva). H. Kerstjens reports no conflicts of interest for this study; unrelated to this study, his institution has received funding for his studies and payments for his consultancy from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Novartis. R. Gans, J. Scherpenisse and J. Schaart report no conflicts of interest for this study.

References

    1. World Health Organization. Corticosteroids for COVID-19: living guidance. Date last accessed: 21 April 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-20...
    1. RECOVERY Collaborative Group . Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384: 693–704. doi:10.1056/NEJMoa2021436 - DOI - PMC - PubMed
    1. Yu LM, Bafadhel M, Dorward J, et al. . Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 2021; 398: 843–855. doi:10.1016/S0140-6736(21)01744-X - DOI - PMC - PubMed
    1. Ramakrishnan S, Nicolau DV, Langford B, et al. . Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021; 9: 763–772. doi:10.1016/S2213-2600(21)00160-0 - DOI - PMC - PubMed
    1. Clemency BM, Varughese R, Gonzalez-Rojas Y, et al. . Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial. JAMA Intern Med 2022; 182: 42–49. doi:10.1001/jamainternmed.2021.6759 - DOI - PMC - PubMed

LinkOut - more resources